Therapeutic Area: Immunology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020
GRAVITAS-301 results show that treatment with itacitinib-corticosteroids combo did not statistically improve overall response rate or non-relapse mortality compared to placebo plus corticosteroids.